Stereodivergent Synthesis of Enantioenriched 4-Hydroxy-2- cyclopentenones by Singh, Gurpreet et al.
Stereodivergent Synthesis of Enantioenriched 4-Hydroxy-2-
cyclopentenones
Gurpreet Singh, Angelica Meyer, and Jeffrey Aubé*
Department of Medicinal Chemistry, University of Kansas, Delbert M. Shankel Structural Biology
Center, 2034 Becker Drive, Lawrence, KS 66047-3761
Abstract
Protected 4-hydroxycyclopentenones (4-HCPs) constitute an important class of intermediates in
chemical synthesis. A route to this class of compound has been developed. Key steps include
Noyori reduction (which establishes the stereochemistry of the product), ring-closing metathesis,
and simple functional group conversions to provide a set of substituted 4-HCPs in either
enantiomeric form.
Building blocks based on 4-hydroxycyclopentenone (4-HCP, 1) are valuable for the
synthesis of biologically active molecules.1 Originally developed for the synthesis of
prostaglandins,2-4 protected 4-HCPs have been converted to numerous natural product
structures, including alkaloids,5-9 terpenes10-12 and others13-20 (Figure 1). This diversity of
targets is such that it is reasonable to consider 1 a “privileged building block” for chemical
synthesis. As such, means of preparing either (R)- or (S)-1 in enantiomerically pure form
with a variety of protecting groups has been vigorously pursued. In this Note, we describe a
simple synthesis of a C2-symmetrical diol, in either enantiomeric form, that can be
converted to 1 and analogues useful in organic synthesis.
Enantioselective approaches to 1 include chiral pool members like tartaric acid, ribose, or
arabinose as starting materials.1 Figure 2a shows Ogura’s method, which as further
developed by Rokach, is the most commonly used method cited in this category.21, 22
Among a number of asymmetric syntheses that have appeared,1, 23 short routes that feature
enantioselective ring opening24 or Noyori reduction25 reactions stand out (Figures 2b and c).
The latter, while brief, seems to be rarely used to prepare 1, perhaps due to the requirement
for severely cryogenic conditions and stoichiometric amounts of chiral reagent.
The preparation of enantiopure 1 by enzymatic catalysis has also been extensively
investigated.1, 26, 27 In particular, the esterase-promoted desymmetrisation of meso-
cyclopentenediol esters is very commonly cited by researchers using 4-HCPs and is one of
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the best-known examples of enzymes in organic synthesis (Figure 2).28, 29 The key step is
the stereoselective hydrolysis of an enantiotopic acetate ester,24 which affords an
intermediate that is converted to TBS-protected enone (R)-1.30-32 This route can be adapted
to the synthesis of the S-configured series by modifying the protection/deprotection steps.33
Having used existing methods for procuring 1 as a starting material5 and contemplating
further such applications, we sought to develop an alternative enantioselective synthesis of
these compounds. We specifically hoped to create a convenient route that would allow ready
and equal access to either enantiomer. In seeking to develop such a route, we noticed that
the simple step of formally inverting one of the alcohol stereocenters in cis-1,2-
dihydroxycyclopen-4-ene changes the timing and nature of the stereochemical issues to be
considered (Figure 3). In the enzymatic route, it is necessary to carry out two
stereocontrolled steps: (1) the synthesis of the meso diacetate (i.e., only cis and not trans,
generally accomplished from cyclopentadiene by 1O2 chemistry or by epoxidation followed
by acetolysis of a derived π-allyl species34) and (2) the enzyme-controlled enantioselective
hydrolysis (Figure 3a).24 In contrast, the corresponding trans-diol would no longer have
planar symmetry but instead be a chiral, C2-symmetric molecule (Figure 3b). Thus, it would
no longer be necessary to differentiate the two identical alcohol groups in future steps.
Moreover, we felt that it would be possible to readily prepare this diol using the known
asymmetric conversion of diketone 2 to 4,35-38 followed by ring-closing metathesis (RCM;
Scheme 1 below). Thus, only a single stereoselective reaction would be required in the
entire synthesis.
To make this happen, commerically available 1,5-dichloro-2,4-pentanedione 2 (also readily
made from acetylacetone35) was reduced as reported by Rychnovsky and coworkers to
afford (R,R)-3 in 40% yield and ca. 97% enantioselectivity (es; Scheme 1).36, 37 Following
Hanson, treatment of diol 3 with the Corey-Chaykovsky reagent39 gave diene diol 4 in 95%
yield.38 Various RCM conditions were tried, with the best results being obtained using
Grubbs II40 catalyst, which provided the cyclized product in 68% yield. In this way, diol 5
could be obtained in multigram amounts (enantiopure 5 is also available via enzymatic
resolution41). We were somewhat surprised to find that it was difficult to selectively carry
out the monoprotection of 5 to afford ethers like 6. Although the initial silylation of 5 could
be easily accomplished, the monoprotected material seemed to more readily undergo a
second reaction with silylating reagent, complicating the route by introducing an
inconvenient separation step.
In contrast, the monoprotection of diol 4 proceeded smoothly to provide a set of alcohols
(R,R)-7 in moderate to excellent yields (Scheme 2). For example, TIPS-protected (R,R)-7a
was obtained in 95% yield from diol 4 using n-BuLi and TIPSCl at −78 °C. As 4-HCPs
appear in different protected guises in synthetic efforts, we prepared TBS-, acyl- and p-
methoxybenzyl-protected versions as shown. Here, monoprotected diol (R,R)-7 was cyclized
via RCM using Grubbs I catalyst42 to obtain the four examples of (R,R)-6 shown in 88–92%
yields. Finally, oxidation of (R,R)-6 with pyridinium chlorochromate provided the targeted
O-protected-4-hydroxy-2-cyclopentenones (R)-1a–d in high enantioselectivities. We
routinely prepare compound 6 in ca. 5–7 g quantities.
This route can be modified for the synthesis of (S)-1 by simply using (R)-BINAP in the
hydrogenation step (Scheme 3). Besides no longer requiring different schemes for preparing
the two enantiomers, the present route proceeds in acceptable overall yields from
commercially available starting materials (26–32%) and compares favorably in number of
steps compared to other methods (5 steps from 2 to either (R)- or (S)-1 as opposed to 9 steps
for the synthesis shown in Scheme 1a).
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Another useful 4-HCP is the α-iodo derivative of enone 1a, which has found applications in
the synthesis of prostaglandins and other natural products (for leading examples, see Roche
and Aitken1). Thus, we transformed both (R)- and (S)-1a into iodides 8 as shown in Scheme
4.
Just as 4-HCPs have been broadly employed in synthesis,2-20 the reduced alcohol precursor
introduced herein should be of comparable utility. We close by providing a few examples of
this potential in Scheme 5. Thus, epoxidation of allylic alcohol 6a provided 9 exclusively in
66% yield (likely due to a reinforcing combination of Henbest-like delivery of peracid43 and
avoidance of the large OTIPS group). Epoxide opening occurred regioselectively with
sodium azide to provide the highly substituted cyclopentane 10 in 69% yield. The stereo-
and regiochemistry of the product 10 was confirmed by 2D NMR analysis of the
corresponding diacetylated compound (see Supporting Information). In addition, amino-
substituted cyclopentane derivatives 12, 13, and 14 were made using simple displacement
chemistry.
In summary, we have demonstrated a convenient synthesis of 4-HCPs, an important class of
privileged building blocks for organic synthesis. The route is scalable for laboratory usage
and provides access to multiple analogs in either enantiomeric series of 4-HCPs using the
identical route (save choice of catalyst).
Experimental Section
General Methods
All reactions were carried out in oven- or flame-dried glassware under argon atmosphere
using standard gas-tight syringes, cannulas, and septa. Et2O, THF and DCM were purified
by passage through neutral alumina columns using a commercial solvent purification
system. All chemicals were used as received from commercial source without further
purification. Flash chromatography was either carried out on a standard grade silica gel (40–
63 mm particle size, 230–400 mesh) with compressed nitrogen as a source of positive
pressure or on an automated purification system using silica flash column. Infrared (IR)
spectra were acquired as thin films. All nuclear magnetic resonance spectra (1H, 13C, COSY
and 1D NOE) were recorded in deutrated chloroform on a 400 MHz instrument with a dual
carbon/proton cryoprobe. Chemical shifts are reported in parts per million (ppm) and are
referenced to the centerline of the solvent (d 7.26 ppm for 1H NMR and 77.23 ppm for 13C
NMR). High-resolution mass spectra (HRMS) were recorded with a time-of-flight mass
spectrometer and an electrospray (ESI) or atmospheric pressure chemical ionization (APCI)
ion source. Observed optical rotations were measured at 589 nm. The er values of
compounds 1a–c and compound 8 were determined by gas chromatography using a
5975CVL MSD triple-axis detector. The er value of the compound 1d was determined by
chiral HPLC on an IC column with a 996 UV-detector.
Known compounds
The following compounds were prepared as previously described: 2,1 (R,R)-3 and its S,S-
enantiomer,35, 36 (R,R)-4 and its S,S-enantiomer.37
(1R,3R)-Cyclopent-4-ene-1,3-diol (5)
A solution of diol 4 (500 mg, 3.91 mmol) in DCM (78.2 mL) and methanol (78.2 mL) was
purged with argon for 5 min and 5 mol% of Grubbs II catalyst (166 mg) was added to it. The
reaction mixture was stirred at rt for 6 h and was quenched with DMSO (1 mL). The
reaction mixture was stirred under air for 5 min and concentrated. The crude product was
purified by silica gel chromatography (100% EtOAc) to afford the product as colorless oil
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(266 mg, 68%). Rf = 0.20 (100% EtOAc); IR (neat) 3420 cm−1; 1H NMR (400 MHz,
CDCl3) δ 6.05–6.01 (m, 2H), 5.07 (t, J = 4.8 Hz, 2H), 2.10 (t, J = 5.0 Hz, 2H), 1.56 (br s,
2H); 13C NMR (101 MHz, CDCl3) δ 137.4, 76.4, 44.4; m/z (ESI+) found [M+H]+ 100.0518,
C5H8O2 requires 100.0524;  +232 (c 1.0, MeOH) [lit41  +228.1 (c 1.04, MeOH)].
(3R,5R)-5-((Triisopropylsilyl)oxy)hepta-1,6-dien-3-ol (7a)
To a stirred solution of (R,R)-4 (2.7 g, 21.1 mmol) in THF (200 mL) at −78 °C, was added
n-BuLi (8.4 mL, 2.5 M in hexanes, 21.1 mmol) dropwise. The solution was allowed to stir
for 20 min at −78 °C followed by the slow addition of TIPSCl (4.9 mL, 21.1 mmol). After 2
h, the reaction was allowed to slowly warm to rt overnight and was quenched with saturated
aq NH4Cl (100 mL). The phases were separated the aq layer was washed with EtOAc (3 ×
100 mL). The combined organic layer was washed with water (100 mL), brine, and dried
(Na2SO4), filtered, and concentrated. The crude extract was purified by silica gel
chromatography (10% EtOAc/hexanes) to afford the product as yellow oil (5.4 g, 96%). Rf =
0.73 (20% EtOAc/hexanes); IR (neat) 3423 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.94 (ddd,
J = 17.1, 10.5, 5.9, 1H), 5.83 (ddd, J = 17.1, 10.4, 5.6, 1H), 5.26 (ddd, J = 12.0, 1.5, 1.5 Hz,
1H), 5.22 (ddd, J = 11.8, 1.4, 1.4 Hz, 1H), 5.14 (ddd, J = 10.5, 1.4, 1.4 Hz, 1H), 5.09 (ddd, J
= 10.5, 1.5, 1.5 Hz, 1H), 4.62–4.56 (m, 1H), 4.47–4.37 (m, 1H), 3.59 (bs, 1H), 1.87 (ddd, J
= 14.0, 9.6, 4.4 Hz, 1H), 1.68 (ddd, J = 14.4, 4.4, 2.8 Hz, 1H), 1.03–1.10 (m, 21H); 13C
NMR (100.6 MHz, CDCl3) δ 140.9, 140.0, 114.9, 114.0, 73.2, 69.6, 43.2, 18.01, 17.99,
12.2; m/z (ESI+) found [M+H]+ 285.2253, C16H32O2Si requires 285.2255;  −5.4 (c
1.0, DCM). (3S,4S)-7a  +5.7 (c 1.5, DCM).
(3R,5R)-5-((tert-Butyldimethylsilyl)oxy)hepta-1,6-dien-3-ol (7b)
To a stirred solution of (R,R)-4 (150 mg, 1.17 mmol) and tert-
butyldimethylsilyltrifluoromethane sulfonate (1.17 mmol, 0.269 mL) in THF (20 mL) at −78
°C, 2,6-lutidine (1.36 mL, 11.7 mmol) was added dropwise via syringe. The solution was
allowed to stir for 2 h at −78 °C. The reaction was quenched with saturated aq NH4Cl (20
mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic phase was washed
with brine, dried (Na2SO4), filtered, and concentrated. The crude product was purified by
silica gel chromatography (10% EtOAc/hexanes) to afford the desired product as colorless
oil (260 mg, 92%). Rf = 0.62 (20% EtOAc/hexanes); IR (neat) 3419 cm−1; 1H NMR (400
MHz, CDCl3) δ 5.91–5.81 (m, 2H), 5.26 (dt, J = 4.0, 1.6 Hz, 1H), 5.22 (dt, J = 3.6 Hz, 1H),
5.09 (ddt, J = 20.0, 10.4, 1.6 Hz, 2H), 4.51–4.47 (m, 1H), 4.41–4.36 (m, 1H), 3.26 (d, J =
2.8 Hz, 1H), 1.77–1.65 (m, 2H), 0.91 (s, 9H), 0.08 (d, J = 12.0 Hz, 6H). 13C NMR (101
MHz, CDCl3) δ 141.0, 140.2, 114.7, 114.0, 72.4, 69.7, 43.3, 25.9, 18.2; m/z (ESI+) found
[M+H]+ 243.1780, C13H26O2Si requires 243.1783;  −11 (c 8.9, DCM).
(3R,5R)-5-Hydroxyhepta-1,6-dien-3-yl acetate (7c)
To a stirred solution of (R,R)-4 (200 mg, 1.56 mmol) in acetonitrile (15 mL), triethyl
orthoacetate (0.43 mL, 2.34 mmol) and p-toluenesulfonic acid (20 mg) were added. The
reaction mixture was stirred at rt for 1 h and a mixture of hydrochloric acid in methanol (0.2
mL HCl in 1 mL MeOH) was added to it. The stirring was continued for another 3 h at rt.
The reaction was quenched with saturated aq NaHCO3 solution (10 mL) and was extracted
with ethyl acetate (20 mL × 3). The combined organic layer was washed with brine, dried
(Na2SO4) and concentrated. Purification via flash column chromatography provided the
desired product as colorless oil (213 mg, 82%). Rf = 0.52 (20% EtOAc/hexanes); IR (neat)
3426 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.87–5.75 (m, 2H), 5.48–5.42 (m, 1H), 5.23 (d, J
= 17.2 Hz, 2H), 5.10 (dd, J = 23.2, 10.4 Hz, 2H), 4.08 (bs, 1H), 2.73 (s, 1H), 2.06 (s, 3H),
1.85–1.64 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 171.1, 140.2, 136.3, 116.6, 114.8, 71.8,
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68.7, 42.0, 21.2; m/z (ESI+) found [M+H]+ 171.1017, C9H14O3 requires 171.1021; 
+16 (c 12.6, DCM).
(3R,5R)-5-((4-Methoxybenzyl)oxy)hepta-1,6-dien-3-ol (7d)
To a 100 mL round bottom flask containing sodium hydride (83 mg of 50% dispersion, 1.72
mmol, prewashed with hexane) under argon, a solution of (3R,5R)-hepta-1,6-diene-3,5-diol
(200 mg, 1.56 mmol) in THF (20 mL) was transferred via syringe at 0 °C. The solution was
stirred for 30 min. at rt and again cooled to 0 °C by keeping in an ice-water bath. A solution
of 4-methyoxybenzyl chloride (366 mg in 2 mL of THF, 2.34 mmol) was added via syringe
and the reaction mixture was stirred at rt for overnight. The reaction was quenched with
saturated aq ammonium chloride solution (10 mL) and was extracted with EtOAc (20 mL ×
3). The combined organic layer was washed with brine, dried (Na2SO4) and concentrated.
Purification via flash column chromatography provided the desired product as colorless oil
(236 mg, 66%). Rf = 0.55 (20% EtOAc/hexanes); IR (neat) 3430 cm−1; 1H NMR (400 MHz,
CDCl3) δ 7.29 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.2 Hz, 2H), 5.93–5.79 (m, 2H), 5.32–5.26
(m, 3H), 5.12 (ddd, J = 10.5, 1.6, 1.6 Hz, 1H), 4.56 (d, J = 11.2 Hz, 1H), 4.47–4.37 (m, 1H),
4.30 (d, J = 11.2 Hz, 1H), 4.16–4.09 (m, 1H), 3.82 (s, 3H), 2.97 (m, 1H), 1.90 (ddd, J =
14.4, 8.4, 3.2 Hz, 1H), 1.73 (ddd, J = 14.8, 8.0, 3.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ
159.3, 140.8, 138.1, 130.2, 129.6, 117.3, 114.1, 113.9, 77.7, 70.2, 69.8, 55.4, 41.8; m/z (ESI
+) found [M+NH4]+ 266.1760, C15H20O3 requires 266.1756;  +139 (c 6.4, DCM).
General procedure for the synthesis of compounds 6a–d
A solution of starting diene (7a–7d) in DCM (0.02 M) was purged with argon for 5 min and
Grubbs-I catalyst (3 mol%) was added to it under argon. The reaction mixture was stirred
for 1 h at 50 °C and quenched with DMSO (1 mL). The solution was stirred under air for 5
min and concentrated. The solvent was evaporated and the crude reaction mixture was
purified by silica gel flash column chromatography to obtain the product (6a–6d).
(1R,4R)-4-((Triisopropylsilyl)oxy)cyclopent-2-enol (6a)
Following the general procedure above, diene 7a (5.00 g, 17.6 mmol) provided
cyclopentenol 6a (4.14 g, 92%) as a colorless oil. Rf = 0.41 (20% EtOAc/hexanes); IR (neat)
3322 cm−1; 1H NMR (400 MHz, CDCl3) δ 6.04–5.80 (m, 2H), 5.24–5.06 (m, 1H), 4.98 (d, J
= 1.9 Hz, 1H), 2.24–1.96 (m, 3H), 1.17–0.91 (m, 22H); 13C NMR (101 MHz, CDCl3) δ
138.5, 135.5, 76.6, 76.2, 44.8, 18.1, 18.0, 12.2; m/z (APCI+) found [M+H]+ 243.1780,
C13H26O2Si requires 243.1783;  +108 (c 2.2, DCM). (1S,4S)-6a  −103.5 (c 3.0,
DCM).
(1R,4R)-4-((tert-Butyldimethylsilyl)oxy)cyclopent-2-enol (6b)
Following the general procedure above, diene 7b (200 mg, 17.6 mmol) provided
cyclopentenol 6b (156 mg, 88%) as a colorless oil. Rf = 0.44 (20% EtOAc/hexanes); IR
(neat) 3327; 1H NMR (400 MHz, CDCl3) δ 5.95–5.90 (m, 2H), 5.08–5.05 (m, 1H), 5.03–
4.97 (m, 1H), 2.08–1.97 (m, 2H), 1.74 (s, 1H), 0.88 (s, 9H), 0.07 (s, 6H). 13C NMR (101
MHz, CDCl3) δ 138.5, 135.6, 76.7, 76.3, 44.6, 26.0, 18.3, −4.5; m/z (APCI+) found [M+H]+
243.1780, C13H26O2Si requires 243.1783;  +89 (c 5.4, MeOH) [lit5  +81 (c
0.059, MeOH)].
(1R,4R)-4-Hydroxycyclopent-2-en-1-yl acetate (6c)
Following the general procedure above, diene 7c (200 mg, 1.17 mmol) provided
cyclopentenol 6c (147 mg, 88%) as a colorless oil. IR (neat) 3374, 1723 cm−1; 1H NMR
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(400 MHz, CDCl3) δ 6.12–6.06 (m, 1H), 6.01–5.95 (m, 1H), 5.81–5.74 (m, 1H), 5.04–4.97
(m, 1H), 2.49 (br s, 1H), 2.17 (ddd, J = 14.8, 6.8, 2.8 Hz, 1H), 2.06 (ddd, J = 14.8, 7.2, 3.6
Hz, 1H), 2.00 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 171.2, 139.9, 132.8, 79.1, 75.8, 40.6,
21.2; m/z (APCI+) found [M+H]+ 243.1780, C13H26O2Si requires 243.1783;  +227 (c
4.9, MeOH) [lit5  +229 (c 0.027, MeOH)].
(1R,4R)-4-((4-Methoxybenzyl)oxy)cyclopent-2-enol (6d)
Following the general procedure above, diene 7d (200 mg, 0.81 mmol) provided
cyclopentenol 6d (159 mg, 89%) as a colorless oil. Rf = 0.40 (30% EtOAc/hexanes); IR
(neat) 3364 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.31–7.26 (m, 2H), 6.93–6.87 (m, 2H),
6.12–6.03 (m, 2H), 5.08–5.00 (m, 1H), 4.85–4.78 (m, 1H), 4.50 (d, J = 11.2 Hz, 1H), 4.45
(d, J = 11.2 Hz, 1H), 3.82 (s, 3H), 2.22 (ddd, J = 14.4, 6.8, 3.2 Hz, 1H), 2.00 (ddd, J = 14.4,
6.8, 2.8 Hz, 1H), 1.85 (bs, 1H); 13C NMR (101 MHz, CDCl3) δ 159.3, 137.9, 135.1, 130.6,
129.5, 113.9, 82.9, 70.9, 55.4, 41.1; m/z (APCI+) found [M+H]+ 243.1780, C13H26O2Si
requires 243.1783;  +139 (c 6.4, DCM).
General procedure for the synthesis of compounds (1a–d)
To a stirred solution of starting cyclopentenol (6a–6d) in DCM (0.1 M) was added
pyridinium chlorochromate (1.5 eq.) at 0 °C. The reaction mixture was stirred at rt for 6 h
followed by filtration over Celite. The Celite bed was washed with diethyl ether. The
combined filtrate was concentrated, and purified by silica gel flash column chromatography
to afford the desired enone (1a–1d).
(R)-4-((Triisopropylsilyl)oxy)cyclopent-2-enone (1a)
Following above general procedure cyclopentenol 6a (2.00 g, 7.81 mmol) provided
cyclopentenone 1a (1.86 g, 94%) as a colorless oil. Rf = 0.30 (10% EtOAc/hexanes); IR
(neat) 1725 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.49 (dd, J = 5.7, 2.3 Hz, 1H), 6.16 (dd, J
= 5.7, 1.2 Hz, 1H), 2.73 (dd, J = 18.1, 5.9 Hz, 1 H), 2.28 (dd, J = 18.1, 2.2 Hz, 1H), 1.21–
0.98 (m, 3H), 1.06 (d, J = 5.4 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 206.5, 163.8, 134.3,
70.9, 45.4, 18.0, 17.9, 12.1; m/z (ESI+) found [M+H]+ 255.1796, C14H26O2Si requires
255.1798;  +53 (c 1.05, MeOH). Chiral GC separation: Astec Chiraldex B-DM fused
silica capillary column, 30m × 0.25 mm × 0.12 μm, temperature gradient from 120 °C–140
°C ramping up at 0.25 °C/min, tR = 37.99 min, tS = 38.70 min, er 97:3. (S)-1a  −57 (c
2.5, MeOH), er ≥ 99:1 [lit.5  −58.8 (c 1.05, MeOH)].
(R)-4-((tert-Butyldimethylsilyl)oxy)cyclopent-2-enone (1b)
Following above general procedure cyclopentenol 6b (120 mg, 0.56 mmol) provided
cyclopentenone 1b (110 mg, 93%) as a colorless oil. Rf = 0.73 (20% EtOAc/hexanes); IR
(neat) 1722 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 5.6, 2.4 Hz, 1H), 6.16 (dd, J
= 5.6, 1.2 Hz, 1H), 5.10–4.94 (m, 1H), 2.69 (dd, J = 18.4, 6.0 Hz, 1H), 2.22 (dd, J = 18.0,
2.0 Hz, 1H), 0.88 (s, 9H), 0.11 (d, J = 4.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 206.4,
163.8, 134.4, 70.8, 44.95, 25.7, 18.1, −4.6 (2); m/z (ESI+) found [M+H]+ 213.1315,
C11H20O2Si requires 213.1311;  +64 (c 1.6, MeOH) [lit.31 [α]D +65.3 (c 0.4,
MeOH)]. Chiral GC separation: Astec Chiraldex B-DM fused silica capillary column, 30m ×
0.25 mm × 0.12 μm, temperature gradient from 105 °C–125 °C ramping up at 1.00 °C/min,
tR = 14.38 min, tS = 15.11 min, er 97:3.
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Following above general procedure cyclopentenol 6c (100 mg, 0.70 mmol) provided
cyclopentenone 1c (91 mg, 92%) as a colorless oil. Rf = 0.73 (20% EtOAc/hexanes); IR
(neat) 1720, 1403, 1031 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.55 (dd, J = 5.6, 2.4 Hz, 1H),
6.31 (dd, J = 5.6, 1.2 Hz, 1H), 5.85–5.80 (m, 1H), 2.80 (dd, J = 18.7, 6.4 Hz, 1H), 2.30 (dd,
J = 18.7, 2.0 Hz, 1H), 2.07 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 205.0, 170.5, 159.0,
137.0, 72.0, 41.0, 20.8; m/z (ESI+) found [M+H]+ 141.0555, C7H9O3 requires 141.0552;
 +100 (c 1.4, MeOH) [lit.31 [α]D +96.1 (c 0.17, MeOH)]. Chiral GC separation: Astec
Chiraldex B-DM fused silica capillary column, 30m × 0.25 mm × 0.12 μm, temperature
gradient from 105 °C–110 °C ramping up at 0.25 °C/min, tR = 9.85 min, tS = 10.77 min, er
98:2.
(R)-4-((4-Methoxybenzyl)oxy)cyclopent-2-enone (1d)
Following above general procedure cyclopentenol 6d (130 mg, 0.59 mmol) provided
cyclopentenone 1d (119 mg, 92%) as a colorless oil. Rf = 0.73 (20% EtOAc/hexanes); IR
(neat) 1714 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 5.7, 2.3 Hz, 1H), 7.29 (d, J =
8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 6.24 (dd, J = 5.7, 1.2 Hz, 1H), 4.78–4.72 (m, 1H),
4.56 (dd, J = 21.3, 11.3 Hz, 2H), 3.81 (s, 3H), 2.67 (dd, J = 18.4, 6.0 Hz, 1H), 2.34 (dd, J =
18.0, 2.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 205.9, 161.3, 159.5, 135.5, 129.5, 129.5,
113.9, 76.5, 71.6, 55.2, 41.8; m/z (ESI+) found [M+H]+ 219.1023, C13H14O3 requires
219.1021;  +51 (c 3.9, DCM). HPLC (Chiralpak IC column n-hexane/i-PrOH = 90/10,
flow rate = 1.0 mL/min, retention time = 38.29 min, er >99:1).
(R)-2-Iodo-4-((triisopropylsilyl)oxy)cyclopent-2-enone (8)
To a stirred solution of I2 (10.7 g, 42 mmol) in Et2O (250 mL) was added pyiridine (2.1 mL,
25 mmol) followed by dropwise addition of (R)-4-((triisopropylsilyl)oxy)cyclopent-2-enone
(8.9 g, 35 mmol) at rt. The reaction flask was completely covered with aluminum foil. After
24 h, the reaction was quenched with aq Na2S2O3 (50 mL). The organic layer was washed
with brine, dried (Na2SO4), filtered and concentrated. The resulting oil was purified using
silica gel chromatography (10% Et2O in hexanes) to afford the product as colorless oil (11 g,
85%). Rf = 0.45 (20% EtOAc/hexanes); IR (neat) 1726 cm−1; 1H NMR (400 MHz, CDCl3) δ
7.84 (d, J = 2.5 Hz, 1H), 6.04 (ddd, J = 6.0, 2.3, 2.3, 1H), 2.90 (dd, J = 18.1, 6.0 Hz, 1H),
2.40 (dd, J = 18.1, 2.1 Hz, 1H), 1.30–0.87 (m, 3H), 1.07 (d, J = 5.3 Hz, 18H). 13C NMR
(100.6 MHz, CDCl3) δ 200.4, 169.4, 105.0, 72.4, 43.0, 18.0 (2), 12.1; m/z (ESI+) found [M
+H]+ 381.0750, C14H25IO2Si requires 381.0746;  +23 (c 4.3, DCM). Chiral GC
separation: Astec Chiraldex B-DM fused silica capillary column, 30m × 0.25 mm × 0.12
μm, temperature 175 °C, tR = 20.99 min, tS = 21.84 min, er 97:3. (S)-8  −25 (c 2.7,
DCM), er 99:1.
(1R,2R,4R,5R)-4-((Triisopropylsilyl)oxy)-6-oxabicyclo[3.1.0]hexan-2-ol (9)
To a solution of (1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (500 mg, 1.95 mmol) in
DCM (20 mL) m-CPBA (657 mg, 2.93 mmol) was added at 0 °C and the reaction mixture
was stirred at rt for 28 h. The reaction mixture was quenched with saturated aq Na2S2O3 (20
mL) and extracted with DCM (3 × 50 mL). The combined organic layer was washed with
saturated aq NaHCO3, brine and dried (Na2SO4). Evaporation of the solvent followed by
flash column chromatography (silica gel, 10% EtOAc/hexanes) gave the desired product as
colorless oil (350 mg, 66%). Rf = 0.37 (10% EtOAc/hexanes); IR (neat) 3320 cm−1; 1H
NMR (400 MHz, CDCl3) δ 4.50 (td, J = 7.9, 0.9 Hz, 1H), 4.42 (d, J = 5.3 Hz, 1H), 3.57–
3.51 (m, 1H), 3.43–3.36 (m, 1H), 2.30 (m, 1H), 1.96 (dd, J = 13.7, 8.0 Hz, 1H), 1.47 (ddd, J
Singh et al. Page 7













= 13.5, 8.0, 5.4 Hz, 1H), 1.12–0.94 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 72.3, 71.7,
58.7, 58.6, 39.1, 18.0, 12.1; m/z (ESI+) found [M+H]+ 273.1883, C14H29O3Si requires
273.1880;  +26 (c 2.5, DCM).
(1R,2S,3R,4R)-2-Azido-4-((triisopropylsilyl)oxy)cyclopentane-1,3-diol (10)
To a solution of (1R,2R,4R,5R)-4-((triisopropylsilyl)oxy)-6-oxabicyclo[3.1.0]hexan-2-ol
(150 mg, 0.55 mmol) in DMF (10 mL), tetrabutylammonium chloride (153 mg, 0.55 mmol)
and sodium azide (358 mg, 5.5 mmol) were added. The reaction mixture was heated at 80 °C
for 24 h. The solvent was removed under redulited pressure and the residue was diluted with
water. The reaction mixture was extracted with ethyl acetate and was dried over anhyd.
Na2SO4. Evaporation of the solvent followed by flash column chromatography (silica gel,
20% EtOAC/hexanes) provided the desired product as colorless oil. Rf = 0.30 (20% EtOAc/
hexanes); IR (neat) 3320, 2102 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.24–4.12 (m, 1H),
3.84 (dt, J = 7.8, 4.9 Hz, 1H), 3.53 (t, J = 7.4 Hz, 1H), 2.28 (d, J = 4.6 Hz, 1H), 2.10 (m,
1H), 2.07–2.00 (m, 2H), 1.66 (m, 1H), 1.13–1.00 (m, 21H); 13C NMR (101 MHz, CDCl3) δ
82.5, 75.1, 72.7, 72.2, 40.2, 17.9, 12.1; m/z (ESI+) found [M+H]+ 316.2055, C14H30N3O3Si
requires 316.2056;  −53 (c 0.6, DCM). Stereo- and regiochemistry of the compound
10 was confirmed by 2D HNMR analysis of the corresponding diacetate, which was made
by treating the former with acetic anhydride and pyridine. IR (neat) 2104, 1747 cm−1; 1H
NMR (400 MHz, CDCl3) δ 5.09 (dd, J = 13.2, 6.1 Hz, 1H), 4.96 (t, J = 5.1 Hz, 1H), 4.34
(dd, J = 11.3, 5.7 Hz, 1H), 3.71 (t, J = 5.5 Hz, 1H), 2.33 – 2.18 (m, 1H), 2.09 (s, 3H), 2.07
(s, 3H), 2.03–1.89 (m, 1H), 1.16–0.90 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 170.2,
170.0, 82.4, 75.8, 73.6, 68.8, 38.0, 21.0, 20.9, 17.82, 17.78, 12.0. Both H1 and H3 show
COSY correlation with H2 that confirms the regiochemistry of azide. Further existence of
1D NOE correlation of H1 with H3 and H2 with H4 confirms the stereochemistry of the
compound 11, hence confirms the structure of 10 retrospectively.
2-((1S,4R)-4-((Triisopropylsilyl)oxy)cyclopent-2-en-1-yl)isoindoline-1,3-dione (11)
To a solution of (1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (300 mg, 1.17 mmol),
phthaliimide (344 mg, 2.34 mmol) and triphenylphosphine (614 mg, 2.34 mmol) in benzene
(10 mL) diethyldiazocarboxylate (0.36 mL, 2.34 mmol) was added dropwise at rt and the
reaction mixture was stirred at rt for 24 h. The reaction mixture was quenched with water
(10 mL) and was extracted with diethylether (3 × 30 mL). The combined organic layer was
washed with brine, dried (Na2SO4), filtered and concentrated. Flash column
chromatography of the crude provided the desired product as viscous oil (319 mg, 68%). Rf
= 0.74 (20% EtOAc/hexanes); IR (neat) 1698 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.85–
7.74 (m, 2H), 7.74–7.62 (m, 2H), 6.01 (ddd, J = 5.6, 2.5, 1.8 Hz, 1H), 5.86 (dt, J = 5.7, 1.7
Hz, 1H), 5.10 (tq, J = 8.4, 2.0 Hz 1H), 4.91 (tq, J = 6.9, 1.7 Hz, 1H), 2.75 (dt, J = 12.3, 7.4
Hz, 1H), 2.20–2.05 (ddd, J = 12.4, 8.4, 6.8 Hz, 1H), 1.16–0.95 (m, 21H); 13C NMR (101
MHz, CDCl3) δ 168.1, 137.1, 134.0, 132.0, 130.8, 123.2, 75.6, 53.4, 40.4, 18.1, 12.21; m/z
(ESI+) found [M+H]+ 386.2144, C22H32NO3Si requires 386.2146;  −97 (c 5.2,
DCM).
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To a solution of 2-((1S,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl)isoindoline-1,3-
dione (100 mg, 0.25 mmol) in THF (5 mL), tetrabutylammonium fluoride (0.5 mL of 1M
solution in THF, 0.5 mmol) was added dropwise and stirred at rt for 1 h. The reaction
mixture was quenched with water (5 mL) and was extracted with ethyl acetate (3 × 30 mL).
The combined organic layer was washed with brine, dried (Na2SO4), filtered and
concentrated. Flash column chromatography (silica gel, 30% EtOAc/Hexane) of the crude
provided the desired product as viscous oil (45 mg, 79%). Rf = 0.20 (20% EtOAc/hexanes);
IR (neat) 3315, 1697 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.86–7.79 (m, 2H), 7.77–7.69
(m, 2H), 6.23 (dt, J = 5.6, 2.0 Hz 1H), 5.75 (dd, J = 5.5, 2.6 Hz, 1H), 5.25 (ddd, J = 9.6, 4.4,
2.2 Hz, 1H), 4.76 (m, 1H), 4.15–4.01 (m, 1H), 2.84 (ddd, J = 15.4, 9.6, 7.8 Hz, 1H), 1.99
(ddd, J = 15.4, 2.0, 1.5 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 168.6, 138.6, 134.4, 131.9,
130.3, 123.5, 76.0, 53.1, 38.3; m/z (ESI+) found [M+H]+ 230.0809, C13H12NO3 requires
230.0817;  −120 (c 3.0, DCM).
(S)-2-(4-Oxocyclopent-2-en-1-yl)isoindoline-1,3-dione (13)
To a solution of 2-((1S,4R)-4-hydroxycyclopent-2-en-1-yl)isoindoline-1,3-dione (40 mg,
0.18 mmol) in dichloromethane (3 mL), pyridiniumchlorochromate (56 mg, 0.26 mmol) was
added at 0 °C. The reaction mixture was stirred at rt for 1 h and was diluted with Et2O (15
mL). The mixture was filtered through a Celite bed. Evaporation of solvent followed by
flash column chromatography (silica gel, 10% EtOAc/hexanes) gave the desired product as
colorless oil (36 mg, 91%). IR (neat) 1721, 1698 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.90–
7.81 (m, 2H), 7.80–7.70 (m, 2H), 7.52 (dd, J = 5.7, 2.4 Hz, 1H), 6.44 (dd, J = 5.7, 2.2 Hz,
1H), 5.54 (ddt, J = 6.9, 3.3, 2.3 Hz, 1H), 2.80 (qd, J = 18.3, 5.2 Hz, 2H); 13C NMR (100.6
MHz, CDCl3) δ 205.3, 167.7, 159.7, 136.3, 134.6, 131.8, 123.7, 49.8, 39.7; m/z (ESI+)
found [M+H]+ 228.0659, C13H10NO3 requires 228.0655;  −224 (c 2.0, DCM) [lit.23
 −230.8 (c 1.07, CHCl3)]
9-((1S,4R)-4-((Triisopropylsilyl)oxy)cyclopent-2-en-1-yl)-9H-purin-6-amine (14)
To a solution of (1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (100 mg, 0.39 mmol),
adenine (106 mg, 0.78 mmol) and triphenylphosphine (205 mg, 0.78 mmol) in THF (10 mL)
diethyldiazocarboxylate (0.12 mL, 0.78 mmol) was added dropwise at rt and the reaction
mixture was stirred for 24 h. The reaction mixture was quenched with water (5 mL) and
extracted with ethyl acetate (3 × 30 mL). The combined organic layer was washed with
brine, dried (Na2SO4), filtered and concentrated. Flash column chromatography (silica gel,
30% EtOAc/hexanes) of the crude provided the desired product as viscous oil (103 mg,
70%). Rf = 0.35 (30% EtOAc/hexanes); IR (neat) 3360 cm−1; 1H NMR (400 MHz, CDCl3) δ
8.37 (s, 1H), 8.07 (s, 1H), 6.26 (dt, J = 5.6, 2.0 Hz, 1H), 6.23 (m, 2H), 6.00 (dd, J = 5.5, 2.2
Hz, 1H), 5.63 (m, 1H), 5.00 (dt, J = 6.8, 2.0 Hz, 1H), 2.96 (ddd, J = 14.9, 8.2, 6.9 Hz, 1H),
1.88 (dt, J = 14.4, 3.1 Hz, 1H), 1.20–0.99 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 155.8,
153.0, 149.7, 139.8, 139.3, 131.3, 119.6, 75.6, 56.7, 42.8, 18.1, 12.1; m/z (ESI+) found [M
+H]+ 374.2370, C19H32N5OSi requires 374.2371;  −53 (c 0.6, DCM).
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Representative applications of 1 in synthesis. Except where noted, these syntheses used
(R)-1 (shown) as starting material.
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Representative approaches to (R)-1: (a) from tartaric acid,21, 22 (b) asymmetric epoxide
opening,24 (c) the Noyori reduction,25 and (d) or enzymatic hydrolysis.28, 30-32, 33
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Stereochemical issues encountered en route to (a) a chiral cis acetoxy alcohol and (b) a
chiral trans diol.
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Synthesis of C2-symmetric diol 5 and initial protection attempts.
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Monoprotection of diol and enone synthesis.
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Iodination of enone 1a; (S)-8 was similarly obtained in ca. 99% es.
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Synthesis of cyclopentane derivatives
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